How iX Biopharma turned conviction into opportunity
After losing a key licensing partner, the Singapore pharmaceutical company continued advancing its lead drug programme. That persistence opened new pathways to commercialisation – and unlocked value beyond the laboratory.
We haven't written up this one. Channel News Asia has the full story — the link below goes straight to it.